Regeneron

President Trump boards Marine One for a trip from the White House to Walter Reed National Military Medical Center for COVID-19 treatment in early October. Trump received Regeneron's antibody cocktail during his illness.

Health & Safety

Low Demand For Antibody Drugs Against COVID-19

11:01am December 22, 2020

by Richard Harris

Monoclonal antibodies to prevent severe COVID-19 aren't being used as widely as expected. Medical staff shortages and patient transportation problems are two of the reasons.

Queue Listen Now

Dr. Deborah Birx, the White House's coronavirus response coordinator, speaks during a briefing with the coronavirus task force at the White House on Thursday. The Food and Drug Administration has granted emergency use authorization for a second antibody t

National
Science
Health & Safety

FDA Grants Emergency Authorization For A 2nd COVID-19 Antibody Treatment

3:43pm November 22, 2020

by Matthew S. Schwartz

The experimental cocktail from the biotech company Regeneron is the same drug President Trump got when he was battling the coronavirus this year. It is designed for mild to moderate cases.

Regeneron has developed a drug called REGN-COV2 that is a combination of two monoclonal antibodies that block the virus that causes COVID-19. The company has a contract to supply up to 300 million doses to the U.S. government.

Health & Safety

Federal Supply Deal For COVID-19 Antibody Treatment Lacks Some Customary Protections

2:19pm November 06, 2020

by Sydney Lupkin

To boost the supply of Regeneron's antibody therapy for COVID-19, the federal government entered into a $450 million supply contract. Details of the deal show some safeguards are missing.